Comparative effectiveness of glasdegib versus venetoclax ...

Comparative effectiveness of glasdegib versus venetoclax ... - PubMed

Background: Two combination therapies recently approved and recommended for use in combination with low-dose cytarabine (LDAC) in acute myeloid leukemia ...

Two combination therapies recently approved and recommended for use in combination with low-dose cytarabine (LDAC) in acute myeloid leukemia patients unfit for ...

Comparative Effectiveness of Glasdegib or Venetoclax in ...

This study indirectly compared OS HRs of GLAS+LDAC and VEN+LDAC in older patients with AML unfit for intensive chemotherapy.

Comparative effectiveness of glasdegib versus venetoclax ...

Results: Differences in efficacy between glasdegib+LDAC and venetoclax+LDAC were suggestive and not statistically significant. Conclusion: With no significant ...

Comparative Effectiveness of Glasdegib or Venetoclax in ...

Adjusted simulated treatment comparisons showed that the overall survival hazard ratios favored glasdegib plus low-dose cytarabine (LDAC) over venetoclax ...

A Comparison of the Effectiveness of Glasdegib versus Venetoclax ...

Overall survival hazard ratios based on adjusted simulated treatment comparisons numerically, but not statistically, favored glasdegib plus low-dose ...

Comparative Effectiveness of Combination Glasdegib+ Low-Dose ...

Among less intensive AML treatments, GLAS+LDAC showed improved efficacy vs LDAC alone in a Phase II randomized controlled trial (RCT). Recently, ...

(PDF) Comparative effectiveness of glasdegib versus venetoclax ...

Patients in the GLAS+LDAC trial were more likely to be male, have secondary AML, and had worse cytogenetic risk profiles than the VEN+LDAC trial ...

Profile of Glasdegib for the Treatment of Newly Diagnosed Acute ...

30-day mortality with azacitidine/venetoclax and Glasdegib/LDAC were comparable at 7% vs 6%, respectively; however, the fatal adverse event rate ...

The comparative effectiveness of glasdegib in combination with low ...

Recently, a randomized, open label study among previously untreated, chemotherapy-ineligible AML patients demonstrated improved overall survival ...

Comparative Efficacy of Venetoclax-Based Combination Therapies ...

VEN + LDAC (SUCRA 91.4%) and VEN + AZA (87.5%) were the highest ranked treatments for complete remission + complete remission with incomplete blood count ...

Glasdegib and venetoclax show similar success for AML | MDedge

Key clinical point: For AML patients unable to undergo intensive chemotherapy, glasdegib and venetoclax were similarly effective, each in ...

Comparative effectiveness of glasdegib versus venetoclax ...

Article: Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia.

ASH 2020: [VIRTUAL] Comparative Effectiveness of Glasdegib or ...

624 - [VIRTUAL] Comparative Effectiveness of Glasdegib or Venetoclax in Combination with Low-Dose Cytarabine Using Simulated Treatment Comparisons open_in_new.

Systematic literature review and indirect treatment comparisons (ITC ...

Systematic literature review and indirect treatment comparisons (ITC) of glasdegib (GLAS) plus low dose ara-c (LDAC) versus a hypomethylating agent (HMA) for ...

(PDF) Overall survival of glasdegib in combination with low-dose ...

In 2018, the FDA approved combination glasdegib (GLAS) plus LDAC based on Phase II results demonstrating improved overall survival (OS) versus ...

results from the randomized, phase 3 BRIGHT AML 1019 trial - Nature

Overall survival (primary endpoint) was similar between the glasdegib and placebo arms in the intensive (n = 404; hazard ratio [HR] 1.05; 95% ...

Randomized comparison of low dose cytarabine with or ... - Nature

The primary endpoint was overall survival. Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, respectively. Median (80% ...

Overall survival of glasdegib in combination with low-dose ...

In 2018, the FDA approved combination glasdegib (GLAS) plus LDAC based on Phase II results demonstrating improved overall survival (OS) versus ...

Glasdegib - an overview | ScienceDirect Topics

In a phase II, randomized trial comparing LDAC with Glasdegib vs LDAC alone in patients with AML or high-risk myelodysplastic syndrome the overall survival was ...